Chemours vs Dow
Dow is the larger business, with $39.97bn of revenue in fiscal 2025 against $5.81bn for Chemours (6.9 times as much). Chemours grew faster (0.4% against -7.0%). Dow kept more of each dollar of sales as profit: a net margin of -6.6% against -6.6%.
| Latest fiscal year | ChemoursCC, 2025 | DowDOW, 2025 |
|---|---|---|
| Revenue | $5.81bn | $39.97bn |
| Revenue growth | 0.4% | -7.0% |
| Net income | −$386m | −$2.62bn |
| Operating margin | — | — |
| Net margin | -6.6% | -6.6% |
| Return on equity | -94.0% | -15.7% |
| Free cash flow | $51.0m | −$1.45bn |
| Cash | $670m | $3.82bn |
| Total debt | $4.18bn | $18.07bn |
| Debt to equity | — | 112.9% |
| Dividend per share | $0.51 | $2.10 |
| Dividend yield | 2.7% | 4.1% |
| Share buybacks | — | $0 |
| Employees | 5,700 | 34,600 |
| Market value | $1.98bn | $24.86bn |
| Price vs our value range | — | Within our value range |
| Moat score | 46 (Moderate) | 31 (Weak) |
| Insider trades, 12 months | 7 buys, 0 sales | 0 buys, 0 sales |